Latest News

This review of the latest dermatological studies includes insights on lichen planus in family members, "washcloth withdrawal," the use of shiitake mushroom extract in dermatology, and more.

The consensus summarizes contemporary real-world data showing that nearly 1 in 5 adolescents and adults with AD receive SCS.

FDA eases iPLEDGE REMS for isotretinoin acne care, allowing some at-home pregnancy tests and fewer lockouts to reduce administrative burden.

Septerna to share phase 1 SEP-631 results at AAAAI, targeting MRGPRX2 to curb mast cell flares and broaden options for refractory CSU.

Catch up on the health and dermatology-related commercials that aired during the 2026 Super Bowl.

REZOLVE-AD shows rezpegaldesleukin delivers durable atopic dermatitis control with monthly or quarterly dosing, supporting Nektar’s phase 3 plans.

Review identifies clinical and lab predictors of early antihistamines CSU and omalizumab CSU response, guiding personalized treatment.

A new molecular test offers clinicians a way to personalize treatment for moderate to severe atopic dermatitis and reduce therapeutic cycling, helping to achieve faster control and a better experience for patients.

In omalizumab-resistant chronic spontaneous urticaria (CSU), tofacitinib rapidly calmed symptoms, but relapses varied.

Takeda’s recent announcement of positive top-line phase 3 results for zasocitinib (TAK-279) places this investigational agent squarely within that evolving conversation.

Bispecific and trispecific biologics are being developed to achieve deeper clearance and more meaningful symptom relief.

Modern hidradenitis suppurativa (HS) management prioritizes restoration of function and quality of life, not just reduction in lesion counts, according to Barry Resnik, MD.

Clinicians are increasingly facing barriers when attempting to prescribe on-label treatments for indicated patients.